343 related articles for article (PubMed ID: 34313532)
21. An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies.
Estep P; Caffry I; Yu Y; Sun T; Cao Y; Lynaugh H; Jain T; Vásquez M; Tessier PM; Xu Y
MAbs; 2015; 7(3):553-61. PubMed ID: 25790175
[TBL] [Abstract][Full Text] [Related]
22. Estimation of the Viscosity of an Antibody Solution from the Diffusion Interaction Parameter.
Shimomura T; Sekiguchi M; Honda R; Yamazaki M; Yokoyama M; Uchiyama S
Biol Pharm Bull; 2022; 45(9):1300-1305. PubMed ID: 36047198
[TBL] [Abstract][Full Text] [Related]
23. Highly sensitive detection of antibody nonspecific interactions using flow cytometry.
Makowski EK; Wu L; Desai AA; Tessier PM
MAbs; 2021; 13(1):1951426. PubMed ID: 34313552
[TBL] [Abstract][Full Text] [Related]
24. Structure-Based Optimization of Antibody-Based Biotherapeutics for Improved Developability: A Practical Guide for Molecular Modelers.
Thorsteinson N; Comeau SR; Kumar S
Methods Mol Biol; 2023; 2552():219-235. PubMed ID: 36346594
[TBL] [Abstract][Full Text] [Related]
25. In Silico Prediction of Diffusion Interaction Parameter (k
Tomar DS; Singh SK; Li L; Broulidakis MP; Kumar S
Pharm Res; 2018 Aug; 35(10):193. PubMed ID: 30128780
[TBL] [Abstract][Full Text] [Related]
26. Antibodies with Weakly Basic Isoelectric Points Minimize Trade-offs between Formulation and Physiological Colloidal Properties.
Gupta P; Makowski EK; Kumar S; Zhang Y; Scheer JM; Tessier PM
Mol Pharm; 2022 Mar; 19(3):775-787. PubMed ID: 35108018
[TBL] [Abstract][Full Text] [Related]
27. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy.
Liu Y; Caffry I; Wu J; Geng SB; Jain T; Sun T; Reid F; Cao Y; Estep P; Yu Y; Vásquez M; Tessier PM; Xu Y
MAbs; 2014; 6(2):483-92. PubMed ID: 24492294
[TBL] [Abstract][Full Text] [Related]
28. Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies.
Mock M; Jacobitz AW; Langmead CJ; Sudom A; Yoo D; Humphreys SC; Alday M; Alekseychyk L; Angell N; Bi V; Catterall H; Chen CC; Chou HT; Conner KP; Cook KD; Correia AR; Dykstra A; Ghimire-Rijal S; Graham K; Grandsard P; Huh J; Hui JO; Jain M; Jann V; Jia L; Johnstone S; Khanal N; Kolvenbach C; Narhi L; Padaki R; Pelegri-O'Day EM; Qi W; Razinkov V; Rice AJ; Smith R; Spahr C; Stevens J; Sun Y; Thomas VA; van Driesche S; Vernon R; Wagner V; Walker KW; Wei Y; Winters D; Yang M; Campuzano IDG
MAbs; 2023; 15(1):2256745. PubMed ID: 37698932
[TBL] [Abstract][Full Text] [Related]
29. Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development.
Tomar DS; Kumar S; Singh SK; Goswami S; Li L
MAbs; 2016; 8(2):216-28. PubMed ID: 26736022
[TBL] [Abstract][Full Text] [Related]
30. A novel screening method to assess developability of antibody-like molecules.
Kohli N; Jain N; Geddie ML; Razlog M; Xu L; Lugovskoy AA
MAbs; 2015; 7(4):752-8. PubMed ID: 25961854
[TBL] [Abstract][Full Text] [Related]
31. Reduction of monoclonal antibody viscosity using interpretable machine learning.
Makowski EK; Chen HT; Wang T; Wu L; Huang J; Mock M; Underhill P; Pelegri-O'Day E; Maglalang E; Winters D; Tessier PM
MAbs; 2024; 16(1):2303781. PubMed ID: 38475982
[TBL] [Abstract][Full Text] [Related]
32. Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactions.
Geng SB; Cheung JK; Narasimhan C; Shameem M; Tessier PM
J Pharm Sci; 2014 Nov; 103(11):3356-3363. PubMed ID: 25209466
[TBL] [Abstract][Full Text] [Related]
33. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.
Nichols P; Li L; Kumar S; Buck PM; Singh SK; Goswami S; Balthazor B; Conley TR; Sek D; Allen MJ
MAbs; 2015; 7(1):212-30. PubMed ID: 25559441
[TBL] [Abstract][Full Text] [Related]
34. Boosting antibody developability through rational sequence optimization.
Seeliger D; Schulz P; Litzenburger T; Spitz J; Hoerer S; Blech M; Enenkel B; Studts JM; Garidel P; Karow AR
MAbs; 2015; 7(3):505-15. PubMed ID: 25759214
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.
Dostalek M; Prueksaritanont T; Kelley RF
MAbs; 2017 Jul; 9(5):756-766. PubMed ID: 28463063
[TBL] [Abstract][Full Text] [Related]
36. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies.
Yang X; Xu W; Dukleska S; Benchaar S; Mengisen S; Antochshuk V; Cheung J; Mann L; Babadjanova Z; Rowand J; Gunawan R; McCampbell A; Beaumont M; Meininger D; Richardson D; Ambrogelly A
MAbs; 2013; 5(5):787-94. PubMed ID: 23883920
[TBL] [Abstract][Full Text] [Related]
37. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
[TBL] [Abstract][Full Text] [Related]
38. Unique Impacts of Methionine Oxidation, Tryptophan Oxidation, and Asparagine Deamidation on Antibody Stability and Aggregation.
Alam ME; Slaney TR; Wu L; Das TK; Kar S; Barnett GV; Leone A; Tessier PM
J Pharm Sci; 2020 Jan; 109(1):656-669. PubMed ID: 31678251
[TBL] [Abstract][Full Text] [Related]
39. Regulatory Approved Monoclonal Antibodies Contain Framework Mutations Predicted From Human Antibody Repertoires.
Petersen BM; Ulmer SA; Rhodes ER; Gutierrez-Gonzalez MF; Dekosky BJ; Sprenger KG; Whitehead TA
Front Immunol; 2021; 12():728694. PubMed ID: 34646268
[TBL] [Abstract][Full Text] [Related]
40. Application of a kosmotrope-based solubility assay to multiple protein therapeutic classes indicates broad use as a high-throughput screen for protein therapeutic aggregation propensity.
Yamniuk AP; Ditto N; Patel M; Dai J; Sejwal P; Stetsko P; Doyle ML
J Pharm Sci; 2013 Aug; 102(8):2424-39. PubMed ID: 23712759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
